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Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—
the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diﬀuse nature of astro-
cytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of
brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment.
Consequently,duringthelasttwodecades,anovelclassofinvestigativedrugcandidatesforthetreatmentofcentralnervoussystem
neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-speciﬁc antigens. The
clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being inves-
tigated.Thusfar,resultsfromongoingclinicaltrialsareencouraging,asdiseasestabilizationandpatientsurvivalprolongationhave
beenobservedinatleast109cases.Thispapersummarizesthemajorﬁndingspertainingtotreatmentwiththediﬀerentantiglioma
cytotoxins at the preclinical and clinical stages.
1.Introduction
National Cancer Institute statistics predicted 22,020 new
cases of malignant brain tumor and 13,140 brain tumor-
related deaths to be recorded in the United States in 2010.
Glioblastoma multiforme (GBM) is the most common pri-
mary malignant brain tumor of the central nervous system
[1]. Hallmarks of GBM include uncontrolled cellular prolif-
eration, diﬀuse inﬁltration, necrosis, angiogenesis, resistance
to apoptosis, and genomic instability. Further, GBM exhibits
considerable intratumoral heterogeneity, both at the cellular
level and at the molecular level. The prevailing treatment
options for GBM include surgery, radiation therapy, and
chemotherapy [2–4]. The median survival for GBM patients
with the standard multimodal therapy, including maxi-
mum safe surgical resection, radiotherapy, and concomitant
chemotherapy with temozolomide (TMZ), is 14.6 months
from the time of diagnosis [5]. Progression-free survival for
recurrent GBM with currently available salvage therapies is
less than 24 weeks, and most patients develop progressive
disease within 8 to 10 months and die from refractory tumor
soon thereafter [6]. Despite these eﬀorts to overcome GBM,
the nonspeciﬁc nature of conventional therapy for brain
tumors often results in damage to the surrounding normal
brain and systemic tissue [7, 8]. As a result, there is an ur-
gent need for the development of therapeutics designed to
speciﬁcally target tumor cells while preserving the adjacent
normal tissue.
Current understanding of molecular abnormalities asso-
ciated with glioma oncogenesis has identiﬁed distinct bio-
logical features common to glioma but atypical in normal
brain tissue [9, 10]. Diﬀerential expression of tumor-speciﬁc
proteins warrants selective targeting of tumor cells, with low
toxicity to the surrounding normal tissue. These proteins are
often described as tumor-associated antigens (TAAs) [11].
A majority of the human tumor antigens are either overex-
pressed normal gene products or those derived from muta-
tions in somatic genes. Hence, TAAs are not strictly tumor
speciﬁc. However, tumors often express these antigens at
higher levels than do normal tissues (often up to 10,000-
fold), and the accessibility of antigens on tumors may there-
fore be greater than in normal tissue [12].2 Clinical and Developmental Immunology
2. Toxin-Based Therapeutics for
Brain Tumor Treatment
The concept of targeting cancer cells using an antibody-
toxin conjugate was investigated in 1970 by Moolten and
Cooperband [13]. As a proof of concept, they explored the
idea of employing an antibody-toxin conjugate against viral
antigens overexpressed on the surface of monkey kidney
cells. Their study successfully demonstrated that antibody-
toxin fusion proteins could be utilized for targeting neoplas-
ticcells.Thedevelopmentofmonoclonalantibodies(mAbs),
and speciﬁcally, the identiﬁcation of tumor-antigen-speciﬁc
mAbs, spearheaded the exploitation of immunotoxins to kill
cancer cells. Immunotoxins, otherwise known as cytotoxins,
are recombinant molecules that speciﬁcally bind to antigens
overexpressed on the surface of a cancer cell [14]. These re-
combinant proteins consist of a speciﬁc antibody or ligand
coupled to a toxin protein. The toxins used in the con-
struction of cytotoxins are natural byproducts of plants,
bacteria, and fungi that inactivate eukaryotic protein synthe-
sis.
The most commonly employed toxins in the construc-
tion of immunotoxins include the bacterial toxins Pseu-
domonas aeruginosa exotoxin A (PE) and diphtheria toxin
(DT) and the plant toxin ricin. All three toxins, PE, DT, and
ricin, are synthesized as single-polypeptide chains consisting
of functionally distinct domains, and these toxins all belong
to the class of A-B toxins, which require cellular uptake
through receptor-mediated endocytosis for activity [15, 16].
The B subunit of these proteins encodes a receptor-binding
domain (B subunit) linked to the A subunit with cytotoxic
activity. Despite their diversity in size, subunit composition,
cell speciﬁcity, and enzymatic activity, these toxins share a
similarfunction—proteinsynthesisinhibition—eitherbyin-
hibiting elongation factor 2 (EF2) or 60S ribosome. A single
molecule of toxin can irreversibly inactivate 300 ribosomes
in 35min and is suﬃcient to kill a cancer cell [16–19].
2.1.Pseudomonas Exotoxin A. Pseudomonas e x o t o xi nAi se x-
pressedasasingle638-amino-acidpolypeptidebytheGram-
negative bacterium Pseudomonas aeruginosa. Upon synthe-
sis, a 25-amino-acid segment is clipped oﬀ the N-terminus
of the proprotein, and a 613-amino-acid mature toxin is sec-
reted [16]. The 66kDa mature toxin comprises three major
functional domains [20, 21] .T h eN - t e r m i n a ld o m a i nI ,
which is subdivided into domains Ia (residues 1–252) and Ib
(365–404), is the receptor-binding domain, and it targets the
low-density, lipoprotein-receptor-related protein (LRP1), or
the closely related variant LRP1B expressed in the plasma
membrane of mammalian cells for subsequent cellular inter-
nalization by receptor-mediated endocytosis [22, 23]. Do-
main II is composed of residues 253–364 and is involved in
toxin translocation and intracellular traﬃcking. The remain-
ing C-terminal residues (405–613), along with a portion of
domain Ib (residues 395–404), make up the catalytically
activedomain,andtheycatalyzetheadenosine-diphosphate-
(ADP-) ribosylation and inactivation of EF2, which leads to
inhibition of protein synthesis followed by cell death [24].
The earliest PE-based therapeutics application was gene-
rated by chemical coupling of the full-length PE to intact
antibodies [25]. Elucidation of the structure and function of
PE led to the development of recombinant immunotoxins,
wherein the receptor binding domain of PE was substituted
with an antibody, the Fv portion of an antibody, a growth
factor, or a cytokine, to generate a higher binding aﬃnity to
cancer cells, through chemical conjugation or recombinant
DNA technology [14].
2.2. Diphtheria Toxin. Diphtheria toxin is secreted by the
Gram-positive bacterium Corynebacterium diphtheriae as a
single polypeptide chain of 535 amino acids [26]. The func-
tional DT is composed of two major domains: amino termi-
nal domain A (1–193 amino acids) carries the active site for
ADP-ribosylation of EF2, and carboxyl terminal domain B
(194–535 amino acids) promotes binding of toxin to cells
and the entry of domain A into the cytosolic compartment.
The human heparin-binding epidermal growth factor-like
precursor (HB-EGF) acts as the receptor for DT on the
plasma membrane of human cells [27]. Once internalized
by receptor-mediated endocytosis, an arginine-rich segment
connectingtheAandBdomainsisreadilycleavedbytrypsin-
like enzymes to yield active fragments A and B [28]. In the
acidic conditions of the late endosome, domain A is translo-
cated into the cytosol [29], where it catalyzes the trans-
fer of the ADP-ribose moiety of nicotinamide adenine dinu-
cleotide (NAD+) to a highly conserved diphthamide residue
(modiﬁed histidine) on the EF2 polypeptide chain, thereby
inactivating it [30–32]. Modiﬁed EF2 can no longer make
new protein, and the cell dies via apoptosis. Recombinant-
DT-based immunotoxins are constructed by mutating or
replacing the carboxyl terminal cell binding domain and
fusing the engineered toxin with a ligand to a cancer cell sur-
face receptor or the Fv fragment of an antibody.
2.3. Ricin. The plant toxin ricin, extracted from the seeds of
Ricinus communis,b e l o n g st oag r o u po ft o x i n sc a l l e dr i b o -
some-inactivating proteins (RIPs) Type II [12]. Ricin is syn-
thesizedasaprecursorproteinof565aminoacids,consisting
of a 24-amino-acid N-terminal signal sequence followed by
the A chain (267 amino acids), which in turn is attached
to the B chain (262 amino acids) by a 12-amino-acid linker
[33]. During biosynthesis, the signal sequence is cotransla-
tionally removed from preproricin to generate proricin, and
the 12-amino-acid linker is cleaved posttranslationally to
yield the mature protein held together by a disulﬁde bond.
The toxic action of ricin is associated with the A chain, and
the B chain functions as a carrier moiety which binds the
toxin to the galactose-containing receptors on the cell sur-
face [34, 35]. Once the A chain reaches the cytosol of the
target cell, it enzymatically attacks the 28S rRNA in the 60S
ribosomal subunit and disrupts protein synthesis [15, 36,
37]. Immunotoxins are generated by chemical cross-linking
of the intact ricin or the recombinant ricin A chain to anti-
bodies directed to antigens overexpressed on the tumor cell
surface.Clinical and Developmental Immunology 3
Table 1: Current listing of immunotoxin trials for brain tumor therapy.
Antigen targeted Immunotoxin characteristics Clinical trial Tumor treated Outcome References
TR: Tf-CRM107
A conjugate of human TR and
full-length DT with two point
mutations in the B chain with
reduced toxin binding
(CRM107)
Phase I/II 44 patients (recurrent
G B Mo rA A )
Median survival 37 weeks;
5/34 CR; 7/34 PR [38, 39]
TR: 454A12-rRA
A conjugate of a mAb
(454A12) to the human TR
and rRA
Phase I Eight leptomeningeal
neoplasia patients Tumor progression [40]
IL-4R: IL-4(38-
37)-PE38KDEL
(NBI-3001)
A circularly permuted
recombinant IL-4 fused to PE Phase I/II 31 patients (25 GBM
and 6 AA)
Median survival 8.2
months; 6 month survival
52%
[41–44]
IL-13R:
IL-13-PE38QQR
(Cintredekin
Besudotox)
A chimeric toxin composed of
hIL-13 and a mutated version
of PE
Phase
I/II/III
Phase II: 51 patients (46
GBM, 3 AA, 1 anaplastic
oligoastrocytoma, 1 AO;
Phase III: 296 patients
(276 GBM conﬁrmed)
Phase II: median survival
45.9 weeks Phase III:
IL13-PE38QQR
compared to GW: Median
survival 36.4 weeks for the
IL13-PE38QQR group
and 35.3 weeks for the
GW group
[45, 46]
EGFR: TP-38
(IVAX)
A chimeric toxin composed of
EGFR ligand TGF-α and PE Phase I
Twenty patients [17
GBM, 1 GSC, 1
metastatic spindle cell
sarcoma, 1 AO]
Median survival 28 weeks [47–49]
Mutant EGFRvIII:
MR1-1-PE38KDEL
An aﬃnity-matured scFv
speciﬁc for EGFRvIII, MR1-1
f u s e dt oP E
Phase I Ongoing
3. Development andEvaluationof
Immunotoxins/CytotoxinsTargetingBrain
Tumor Antigens in the Preclinicaland
ClinicalSettings
In 1905, Paul Ehrlich proposed the idea of using antibodies
to deliver chemotherapeutic agents. Since then, the utility of
antibodies to speciﬁcally diagnose, localize, and treat human
tumors has been actively pursued. A tumor-speciﬁc antigen
expressed only by the tumor cell and not by normal cells is
hard to discover. However, many molecular targets that are
expressed in much higher concentrations on glioma cells,
compared to those on normal neural tissues, have been iden-
tiﬁed, and mAbs against these glioma-associated antigens
(GAAs) have been developed [50]. Several of these antigens
and their therapeutic utilities are discussed below and sum-
marized in Table 1.
3.1. Transferrin Receptor. The transferrin receptor (TR) is a
transmembraneglycoproteinwhichmediatesthecellularup-
take of iron from the plasma glycoprotein transferrin [51].
TRisexpressedinallnucleatedcellsofthebody,withexpres-
sionlevelscorrespondingtotheirironrequirementsandpro-
liferativestatus. Dueto the increased growth and rapid proli-
feration capacity of cancer cells, overexpression of TR has
been observed in several cancer types [52]. The use of an
anti-TR mAb chemically coupled to the subunits of DT or
ricin to target tumor was ﬁrst investigated by Trowbridge
and Domingo [53]. Since then, several anti-human TR mAb
ricin-based immunotoxins have been successfully tested in
vitro for the treatment of malignant brain tumors [54, 55].
The in vitro and in vivo eﬃcacy of two such targeted protein
toxins was studied: (1) Tf-CRM107, a conjugate of human
TR and full-length DT with two point mutations in the B
chain with reduced toxin binding (CRM107) [56], and (2)
454A12-rRA, a conjugate of a mAb (454A12) to the hu-
man TR and recombinant ricin A chain (rRA), against TR-
expressing brain tumors. Both compounds exhibited signif-
icant killing of human glioblastoma cell lines in vitro and in
vivo. However, Tf-CRM107 was more potent than 454A12
[57–59].
Leptomeningeal neoplasia occurs in 5%–20% of all can-
cer patients and results in a very poor prognosis, with a med-
ian survival of only a few months [60] .Ap h a s eIs t u d yw a s
conducted to identify the toxicity, pharmacokinetics, and
antitumor activity with the 454A12-rRA immunotoxin in
eight patients with leptomeningeal spread of systemic neo-
plasia (six patients with breast carcinomas, one patient with
melanoma, and one patient with leukemia) [40]. In four of
the eight patients, the lumbar cerebrospinal ﬂuid (CSF)
tumor cell counts dropped by more than 50% within 5–7
days after the intraventricular delivery of 454A12-rRA; how-
ever, no patient had the CSF cleared of tumor, and evidence
of tumor progression was demonstrated in seven of the eight
patients after treatment.
The toxicity, maximum-tolerated dose (MTD), and eﬃ-
cacy of Tf-CRM107 was evaluated in a phase I single-center,
dose-escalating, single-arm trial, in patients with malignant4 Clinical and Developmental Immunology
brain tumors refractory to conventional therapy [38]. The
Tf-CRM107wasdirectlydeliveredtotumorandsurrounding
inﬁltrated brain by high-ﬂow interstitial microinfusion.
Eighteen patients were enrolled for the trial, and ﬁfteen pa-
tients were evaluated for radiographic evidence of tumor
regression.FollowingTf-CRM107infusion,a≥50%decrease
in tumor volume occurred in nine of the 15 patients (60%)
evaluated [38]. The treated tumors showed complete res-
ponses (CRs) in two of the patients, with one of these two
patients showing no evidence of tumor for 23 months after
a single infusion of Tf-CRM107 into a progressing recurrent
GBM [38]. The results demonstrated that Tf-CRM107, deli-
vered via convection-enhanced drug delivery (CED), can
elicit antitumor activity without severe neurologic or sys-
temic toxicity in malignant brain tumor patients.
A phase II multicenter trial by intratumoral CED infu-
sion of Tf-CRM107 for patients with recurrent GBM or
anaplastic astrocytoma (AA) was launched. Patients then re-
ceived Tf-CRM107 infusions (0.67μg/mL, up to 0.40mL/h),
for 4-5 days until a volume of 40mL was delivered [39]. Four
to 10 weeks afterinitial infusion the patients werereadmitted
to receive a second treatment. Eﬃcacy response for the
treated tumors was categorized as complete response, partial
response (PR), stable disease, or progressive disease. Of 34
evaluable patients, the Tf-CRM107 treatment resulted in
CRs in a total of ﬁve patients and PRs in seven patients
(35%, P<0.0001). The median survival time was 37 weeks,
13/44 patients (30%) survived beyond 12 months from the
time of the ﬁrst infusion, and one patient survived 1144
days. In 8 of the 44 12-month survivors (14%), Tf-CRM107
infusions caused symptomatic progressive cerebral edema,
which responded to medical management. Seizures were
seen in 3 of these 44 patients (7%) and were treated by
anticonvulsant therapy [39]. The phase II study indicated
that tumor response can be obtained in a signiﬁcant percen-
tage of recurrent or refractory GBM or AA patients, and the
magnetic resonance imaging (MRI) tumor response corre-
lated with a more favorable survival. A phase III clinical
trial with Tf-CRM107 for patients with nonresectable, prog-
ressive, or recurrent GBM who had failed conventional ther-
apy was initiated in 2004. But the study was discontinued in
2007 because of a failure to demonstrate a positive thera-
peutic response. Future trials could focus on increasing the
treatment eﬃcacy of Tf-CRM107 by combining this agent
with other toxin conjugates targeted to diﬀerent GAAs or
by employing a genetically engineered Tf with decreased
iron release rate and increased cellular association and cyto-
toxicity [61].
3.2. Interleukin-4 Receptor. Interleukin-4 (IL-4) is a pleio-
tropic cytokine produced by TH2-type CD4+ T cells, baso-
phils, and mast cells, in response to receptor activation. IL-4
regulates the diﬀerentiation of antigen-stimulated naive T
cells and the speciﬁcity of immunoglobulin class switching
by B cells [62]. IL-4 functions by signaling through its recep-
tor. IL-4 receptors are expressed in several cell types, includ-
inghematopoietic,endothelial,muscular,andneuronalcells,
and are usually expressed at low levels ranging from 100 to
5000 receptors per cell [62]. Two types of IL-4 receptors have
been identiﬁed so far. Type I receptors consist of a 140-kDa
protein, IL-4Rα (also known as IL-4Rβ), and the γ common
(γc)chain[63,64]. Type II receptors are composed of IL-4Rα
and IL-13Rα1 (also known as IL-13Rα ) chains [65, 66]. The
type II receptor is expressed mainly in nonhematopoietic
cells. Ligand-induced heterodimerization of IL-4R activa-
tes cytoplasmic tyrosine kinases (Janus kinase family-Jak),
which in turn phosphorylates cellular substrates and initiates
signaling cascades leading to cellular proliferation and gene
expression [62].
Several human tumors are known to express IL-4R, in-
cludingmalignantmelanoma,breastcarcinoma,ovariancar-
cinoma,andrenalcellcarcinoma[67,68].Achimericprotein
composed of human IL-4 and a full-length PE molecule with
mutation in the cell binding domain of PE, hIL4-PE4E, was
cytotoxic (with 50% inhibition of protein synthesis [IC50]
occurringinthe12–120-pMrange)toawiderangeofhuman
cancer cell lines [69, 70]. The high-aﬃnity IL-4 receptors
were also demonstrated to be present on human GBM,
neuroblastoma, and glioma cells, and IL-4-PE4E was found
tobehighlycytotoxic(withIC50 intherangeof85–2000pM)
to the neurological tumor cells [71]. Attachment of the large
PE molecule to the carboxyl terminus of hIL-4 decreased the
aﬃnity of the hIL-4-PE4E toxin by 15–20-fold compared to
that of native hIL-4 [69]. To overcome this hurdle, a circu-
larly permuted recombinant IL-4 was developed by connect-
ing the IL-4 amino acids 38–129 via the linker GGNGG to
amino acids 1–37, which were in turn fused to a redesigned
PE containing amino acids 253–364 and 381–608, followed
by a new endoplasmic reticulum retention sequence, KDEL
[72, 73]. This new toxin, termed IL-4(38-37)-PE38KDEL,
exhibited improved binding aﬃnity, cytotoxicity (with IC50
inthe6–17-pMrange),andinvivoantitumoractivityagainst
IL-4R-expressing cancers [72, 73]. Further studies demons-
trated the expression of IL-4 receptor in malignant brain
tumor samples, which were highly sensitive to IL-4(38-37)-
PE38KDEL treatment, whereas it was less toxic to hemato-
poietic and normal brain cells [74, 75]. Intratumoral admin-
istration of IL-4(38-37)-PE38KDEL into U251 glioblastoma
ﬂank tumors in nude mice induced complete regression of
tumors in all of the animals without any toxicity [76]. Pre-
clinical investigation in rats demonstrated that signiﬁcant
cytotoxic activity against malignant astrocytic tumors could
beachievedbyintrathecaladministrationofIL-4(38-37)-PE-
38KDEL, with no toxicity to normal cells [75].
Based on the preclinical studies, a phase I clinical trial
was initiated to determine the safety and tolerability of IL-4
(38-37)-PE38KDEL (NBI-3001) in recurrent human malig-
nantgliomawheninjectedintratumorallybyCEDby2-3cat-
heters [41]. No histological evidence of neurotoxicity to nor-
mal brain was identiﬁed in any patient. Six of nine patients
showed glioma necrosis, as evidenced by decreased enhance-
ment on MRI. Of six patients, one patient remained disease
free for >18 months after the procedure [41]. A multicenter
open-label dose-escalation trial was launched to determine
the MTD, volume, and safety of IL-4(37-38)-PE38KDEL
when injected stereotactically [42, 43]. A total of 31 patients,
25 GBM and 6 AA, were assigned to one of four dose groups
in a dose-escalation fashion: 6μg/mL in 40mL, 9μg/mL inClinical and Developmental Immunology 5
40mL, 15μg/mL in 40mL, or 9μg/mL in 100mL of IL-4(37-
38)-PE38KDEL administered intratumorally via stereotac-
tically placed catheters [42, 43]. No drug-related systemic
toxicity was evident in any treated patients, and treatment-
relatedadverseeﬀectswerelimitedtothecentralnervoussys-
tem (CNS). Drug-related grade 3 or 4 CNS toxicity was ob-
served in a total of 39% patients in all groups, and in 22% of
patients at the MTD dose of 6μg/mL in 40mL. The overall
median survival for the whole group was 8.2 months, with
a median survival of 5.8 months for the GBM patients. Six-
month survival was 52% and 48%, respectively. MRI of the
brain showed areas of decreased signal intensity within the
tumor consistent with tumor necrosis following treatment in
many patients [42, 43].
A multicenter, randomized, open-label phase II study
with IL-4(38-37)-PE38KDEL administered to recurrent
GBM patients was conducted to evaluate the eﬃcacy, safety,
and tolerability of the toxin after continuous intratumoral
infusion of the toxin at total doses of up to 90μg followed
by surgical resection of the tumor [44]. A total of 30 adult
patients with unilateral, unifocal tumor with a volume of 5–
80mLandaKarnofskyperformancescore(KPS)of ≥70were
enrolled (ClinicalTrial.gov identiﬁer: NCT00014677). The
results of the study have not been published. Currently, there
are no phase III protocols involving IL-4(38-37)-PE38KDEL.
3.3. Interleukin-13 Receptor. Interleukin-13 (IL-13) is a
12-kDa cytokine that is expressed by T cells, mast cells, and
Epstein-Barr-virus- (EBV-) transformed B cells. IL-13 pro-
tein has 30% amino acid sequence homology with the IL-4
protein, and, hence, these cytokines share a variety of func-
tions [65]. Functions of IL-13 include upregulation of major
histocompatibility complex (MHC) class II and low-aﬃnity
IgE receptor expression on monocytes, induction of IgE and
IgG4 class switching in B cells, and upregulation of vascular
cell adhesion molecule-1 (VCAM-1) expression on endothe-
lial cells [65]. Two receptors for IL-13 have been identiﬁed:
IL-13Rα2 ,am e m b r a n e - b o u n dp r o t e i nw i t hah i g ha ﬃnity
for IL-13, and IL-13Rα1, a low-aﬃnity IL-13 binding chain.
IL-13Rα1 upon interaction with the IL-4Rα binds IL-13 with
high aﬃnity and activates an intracellular signaling pathway
in tumor, endothelial, ﬁbroblast, and immune cells [77]. IL-
13Rα2 binds IL-13 in an IL-4-independent manner [78].
The IL-13Rα2 is expressed in many human tumors, in-
cluding GBM, acquired immunodeﬁciency syndrome-asso-
ciated Kaposi sarcoma, squamous cell carcinoma of the head
andneck,pediatricbraintumors,andmedulloblastoma[78–
84]. Human glioma cells overexpressing IL-13R were highly
sensitive (IC50 at <20pM) to a chimeric toxin composed
of hIL-13 and a mutated version of PE, PE38QQR-IL-13-
PE38QQR, which has lysines 590 and 606 replaced with glu-
tamines and lysine 613 with arginine [80]. A second fusion
protein composed of hIL-13 and the ﬁrst 389 amino acids of
DT, DT390IL13, exhibited signiﬁcant cytotoxicity against es-
tablished and primary GBM cell lines and completely reg-
ressed GBM tumors in nude mice [85, 86]. A recombinant
immunotoxin, anti-IL-13Rα2(scFv)-PE38, was also cons-
tructed by fusing human single-chain variable fragments
(scFvs), isolated from a phage library, against IL-13Rα2w i t h
PE. The antitumor activity against GBM tumors with anti-
IL-13Rα2(scFv)-PE38 was not higher than that with IL-13-
PE38 [87].
Encouraging preclinical results have led to the initiation
of several phase I/II clinical trials in recurrent malignant gli-
oma patients with IL13-PE38QQR (also known as Cintre-
dekin Besudotox; CB; NeoPharm, Lake Bluﬀ,I L ) .I n t r a c e r e -
bral CED of IL-13-PE38QQR following tumor resection was
evaluatedinthreephaseIclinicaltrials.Theaimwastoassess
thetolerabilityofdiﬀerentconcentrationsandinfusiondura-
tions, tissue distribution, and methods for optimizing deliv-
ery of IL-13-PE38QQR [45]. A total of 51 patients (46 GBM,
3 AA, 1 anaplastic oligoastrocytoma, 1 anaplastic oligoden-
droglioma) were treated. All patients underwent tumor re-
section followed by intraparenchymal placement of one to
threecathetersinareasatriskforresidualinﬁltratingtumors.
IL-13-PE38QQR was then administered by CED at a ﬁxed
total infusion rate of 0.750mL/h divided by the number of
cathetersfor96h.AnintratumoralIL-13-PE38QQRinfusion
preceding tumor resection was also performed in 18 of 51
patients to assess drug distribution. Intraparenchymal con-
centrations of 0.25μg/mL and 0.5μg/mL were well tolerated
with infusion durations up to 6 days. The MTD for intra-
parenchymal concentration was 0.5μg/mL, and tumor nec-
rosis was observed at this concentration. Postoperative cath-
eter placement appears to be important for optimal drug
distribution.IL-13-PE38QQRandprocedure-relatedadverse
events were primarily limited to the CNS. An overall median
survival of 45.9 weeks was observed for the entire group
posttreatment (N = 51). Median survival for GBM patients
after treatment was 42.7 weeks (N = 46). The median sur-
vivalwas55.6weeksforGBMpatientswithtwoormoreopti-
mallypositionedcatheters(N = 24)and37.4weeksforGBM
patients with fewer than two catheters optimally positioned
(N = 19). Nine patients (17.6%) and seven patients (13.7%),
all with GBM except one, had a prolonged progression-free
survival beyond 1 and 2 years, respectively, with patient
follow-up extending beyond 5 years [45].
A phase III randomized evaluation of CED of IL13-PE-
38QQR compared to Gliadel wafer (GW; Rhone-Poulenc
Rorer, Inc. (Paris, France), and Guilford Pharmaceuticals,
Inc. (Baltimore, MD, USA)) with survival endpoint trial
(called the PRECISE Trial), was conducted, and 296 patients
were enrolled at 52 centers worldwide [46]. The aim of the
study was to determine whether IL-13-PE38QQR therapy in
recurrent GBM patients improved the overall survival dura-
tion, safety, and quality of life as opposed to GW treatment.
Patients were randomized, 192 to receive IL-13-PE38QQR
and 104 to receive GW. Of these 296 patients, a total of 276
patients had histopathologic conﬁrmation of GBM. IL13-
PE38QQR (0.5μg/mL; total ﬂow rate of 0.75mL/h) was
administered over 96h via 2–4 intraparenchymal catheters
placed 2–7 days after resection in areas at greatest risk for
inﬁltrating disease or in the vicinity of any residual, solid,
contrast-enhancing disease. GWs (3.85%/7.7mg carmustine
per wafer; maximum 8 wafers) were placed immediately
following tumor resection [46]. The total number of patients
available for safety analysis with IL13-PE38QQR or GW6 Clinical and Developmental Immunology
(i.e., they received any study drug) and eﬃcacy analysis was
269 and 188, respectively. Median survival for the GBM pop-
ulationwas36.4weeks(9.1months)fortheIL-13-PE38QQR
group and 35.3 weeks (8.8 months) for the GW group (P =
0.476). Median survival in the eﬃcacy evaluable population
was 45.3 weeks (11.3 months) for IL-13-PE38QQR and 39.8
weeks (10 months) for GW (P = 0.310) [46]. The safety
and adverse events proﬁles were similar for both treatment
groups, with the exception of pulmonary embolism, which
was higher in the IL-13-PE38QQR group (8% versus 1%,
P = 0.014). The PRECISE is the ﬁrst and largest study using
CED with an active comparator in recurrent GBM patients.
Although IL-13-PE38QQR was well tolerated, there was no
survival advantage of IL13-PE38QQR administered via CED
compared with GW.
Since earlier studies described high levels of IL-13Rα2
expression in a signiﬁcant proportion of GBM samples, the
IL-13Rα2 levels were not examined in the GBM patients
included in the current trial. A later study revealed IL-13Rα2
to be expressed in only 44%–47% of GBM specimens, and
even within individual positive tumors the distribution of
IL-13Rα2 was highly heterogeneous [88]. This study under-
scored the potential beneﬁts of prescreening patients for IL-
13Rα2 expression prior to enrollment into IL13-PE38QQR-
based targeted therapies. Further, the current trial did not
includereal-timeimagingtoascertainiftherequisiteconcen-
tration of therapeutic agent was delivered to the tumor site.
Hence, optimization of several parameters, including initial
screening of patients for target antigen (IL-13Rα2) expres-
sion, optimal catheter positioning, and real-time drug deliv-
eryimaging,shouldincreasethesuccessrateoffutureclinical
trials.
3.4. Epidermal Growth Factor Receptor. The epidermal
growth factor receptor (EGFR), a 170-kDa, transmembrane
glycoprotein, is composed of three functional domains—an
extracellular ligand-binding domain (ECD), an anchoring
membrane-spanning region, and an intracellular catalytic
domain that functions as a tyrosine kinase receptor. EGFR
is stimulated by binding of its ligands, such as transforming
growth-factor- (TGF-) α or EGF, to its ECD [89, 90]. Both
EGF and TGF-α are small mitogenic proteins, each com-
posed of 53 and 50 amino acid residues, respectively. TGF-α
shares about 30% sequence identity with EGF, including the
conservation of all six cysteines, which are involved in the
formation of three intramolecular disulﬁde bonds [91]. The
disulﬁde bonds are essential for their biological activity
[92]. TGF-α competes with EGF for the same membrane-
bound receptor sites [89]. Ligand binding induces recep-
tor dimerization and activates a tyrosine-speciﬁc protein
kinase activity [93] involved in controlling epithelial-cell
growth and proliferation. Ultimately, the receptor-ligand
complexes are internalized, and the EGFR signal is termi-
nated.
EGFR overexpression is frequently observed in a wide
variety of human cancers, including breast [94], lung [95],
head and neck [96], prostate [97], bladder [98], colorectal
[99],andinovariancarcinoma[100],aswellasbraintumors
[101, 102]. The ratio of EGFR expression in glioma versus
normalcontrolbrainspecimenshasbeenshowntobeashigh
as 300-fold [103]. EGFR is the most frequently ampliﬁed
gene in GBM [104]. Correlating with the gene ampliﬁcation,
the protein is overexpressed in about 60%–90% of GBM
cases. Even in the absence of gene ampliﬁcation, protein
overexpression has been observed in 12%–38% of GBM
patients [105], which could be due to aberrant translational
and posttranslational mechanisms. Preclinical studies have
shown that EGFR activation, in addition to protecting
cells from apoptosis, also induces several tumorigenic pro-
cesses, including proliferation, angiogenesis, and metastasis
[106].
Several chimeric toxins composed of TGF-α and PE, for
example, TGF-α-PE38 and TGF-α-PE40, were constructed.
These toxins were highly eﬀective in retarding tumor growth
and increasing the survival of athymic nude mice that were
implanted with GBM or medulloblastoma xenografts [107,
108]. An anti-EGF receptor antibody (425.3), chemically
conjugated to the whole PE molecule, was also investigated
for the treatment of human gliomas. Treatment of intrac-
erebral U87MG tumors in nude rats with 4μg of 425.3-PE
increased symptom-free survival from 23 days to 40 days,
with 2/9 rats surviving more than 90 days [109]. Further, a
DT-based fusion protein was produced in conjunction with
EGF, DAB389EGF, which exhibited signiﬁcant cytotoxicity in
vitro (with IC50 in the 0.4–50 pM range) and tumor regres-
sion in vivo against human GBM cells [47, 110].
The toxicity of TGF-α-PE38 (TP-38, IVAX) was assessed
inathymicmice,athymicrats,andRhesusmacaques,andthe
MTD was determined to be 0.100μg, 0.666μg, and 2.0μg,
respectively. Based on these studies, the estimated MTD for
humans was 200μg[ 48]. Based on these preclinical data, a
phase I study was initiated to deﬁne the MTD, dose-limi-
ting toxicity (DLT), and eﬃcacy of TP-38 delivered by CED
for recurrent malignant glioma patients [49]. Twenty adult
patients (17GBM,1gliosarcoma (GSC),1metastatic spindle
cell sarcoma, 1 anaplastic oligodendroglioma (AO)) with
aK P S≥60 were enrolled. TP-38 was infused over 50h at
a ﬂow rate from each catheter of 0.4mL/h for a total
volume of 40mL. Three escalating concentrations of TP-38,
25ng/mL, 50ng/mL, and 100ng/mL, were selected for study.
In the last eight patients, coinfusion of 123I-albumin was per-
formed to monitor distribution within the brain [49]. Med-
ian survival for all patients after TP-38 treatment was 28
weeks and for those without radiographic evidence of resi-
dual disease, 33 weeks. Of the 15 patients treated with resi-
dual disease, two (13.3%) demonstrated radiographic res-
ponses, including one patient with GBM who had a nearly
complete response and remains alive >260 weeks after ther-
apy.Coinfusionof 123I-albumindemonstratedthathighcon-
centrations of the infusate could be delivered >4cm from
the catheter tip. However, only 3 of 16 (19%) catheters pro-
duced intraparenchymal infusate distribution, while the
majority leaked infusate into the cerebrospinal ﬂuid spaces.
Due to adequate TP-38 delivery failure in a majority of the
patients,thestudywashaltedatadoseof100ng/mL,without
reachinganMTD.TwoDLTswereseen,andbothwereneuro-
logic [49]. Intracerebral CED of TP-38 was well tolerated
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<100ng/mL.Futurestudiesshouldconcentrateonoptimiza-
tion of CED delivery technique and drug infusion para-
meters.
3.5. Mutant Epidermal Growth Factor Receptor Variant III.
Several EGFR deletion mutants have been identiﬁed, the
mostcommononebeingEGFRvIII,whichispresentin20%–
50% of GBMs with EGFR ampliﬁcation [111]. The mutant
EGFRvIII contains a deletion of exons 2–7 of the EGFR gene,
which is characterized by an in-frame deletion of 801 base
pairs of the coding region [112]. This deletion creates a novel
glycine residue at the fusion junction at position 6, between
amino acid residues 5 and 274, generating a tumor-speciﬁc
protein sequence, that is, expressed speciﬁcally on tumor
cells but not on normal tissues. EGFRvIII is a constitutively
active receptor tyrosine kinase which is not further activated
by EGFR ligands [113]. Like its wild-type counterpart,
EGFRvIIIiswidelyexpressedinmalignantgliomas[114]and
carcinomas, including head and neck [115] and breast can-
cers [116]. Overexpression of EGFRvIII induces resistance
in glioma cells to commonly used chemotherapeutic agents
[117]. Hence, EGFRvIII is a desirable target for therapeutic
intervention.
The therapeutic eﬃcacy of three anti-EGFRvIII-speciﬁc
mAbs, L8A4, Y10, and H10, chemically coupled to PE35-
KDEL, was evaluated against a mutant EGFRvIII-expressing
cell line. All three immunotoxins were cytotoxic, with an
IC50 in the range of 15–50pM [118]. An scFv speciﬁc for
EGFRvIII, MR1 (mutant receptor), was isolated from an
immunized phage library and was fused to an immuno-
toxin variant of PE, PE38KDEL. The cytotoxicity of MR1-
PE38KDEL was tested against EGFRvIII-transfected malig-
nant glioma cells, and the IC50 of MR1-PE38KDEL on these
cells was in the range of 110–160pM [119]. The toxicity
and therapeutic eﬃcacy of MR1-PE38KDEL was tested in
an athymic rat model of neoplastic meningitis induced by
intrathecal inoculation of an EGFRvIII-expressing human
glioma [120]. A dose escalation study compared the survival
ofthreeequaldosesof1,2,and3μgofMR1-PE38KDELwith
saline or 3μg of a control immunotoxin. All saline or control
immunotoxin-treated animals died, with median survival of
7 and 10 days, respectively. There were 75% (1-μgg r o u p )
and 57% (2- or 3-μg group) long-term survivors with MR1-
PE38KDEL treatment. None of the MR1-PE38KDEL-treated
groups reached median survival by the termination of the
study at 53 days. Median survival was estimated to be >53
days. Compartmental therapy with three doses of 2μgo f
the MR-1 immunotoxin was eﬀective in the treatment of
EGFRvIII-expressing neoplastic meningitis, with no clinical
or histopathological eﬀects on nontumor-bearing animals
[120].
An aﬃnity-matured variant of MR1, termed MR1-1,
with increased aﬃnity to EGFRvIII, was generated for tar-
geted glioma therapy [121]. The MR1-1 scFv was then fused
to PE38, to generate MR1-1-PE38. As compared to the
parental MR1-PE38, MR1-1-PE38 exhibited improved cyto-
toxic activity against the EGFRvIII-expressing NR6M cell
line [121]. A phase I study to determine the MTD and DLT
of MR1-1-PE38KDEL delivered intracerebrally by CED in
patients with supratentorial malignant brain tumors is cur-
rentlyongoing(ClinicalTrials.govIdentiﬁer:NCT01009866).
The study design includes infusion of MR1-1-PE38KDEL by
CED using two intracerebral catheters. 124I-labeled albumin
iscoinfusedwithgadoliniumtomonitorradiographicallythe
volume of drug distribution and leakage into the CSF space
after drug infusion. A starting total drug dose of 0.5μg
(1/20th of the MTD in rats) at a ﬁxed ﬂow rate of 0.5mL/h
is infused from each of the two catheters. A total of 96mL
of drug solution is delivered over 96h. MR1-1-PE38KDEL
dose escalation will be accomplished by increasing drug con-
centration while allowing ﬂow rate and infusion volume to
remain unchanged. Supratentorial malignant brain tumor
patients with KPS >70 and expressing the EGFRvIII target
antigen will be enrolled in this trial. The distribution of
MR1-1-PE38KDEL at a concentration of 25ng/mL by CED
was monitored by coinfusion with the low molecular weight
tracer gadolinium-diethylene triamine pentaacetic acid (Gd-
DTPA) and 124I-labeled human serum albumin in a malig-
nant glioma patient [122]. This study demonstrated that Gd-
DTPA coinfusion is able to precisely demonstrate the distri-
bution of MR1-1-PE38KDEL at the tumor site (Figure 1).
Monitoring of MR1-1PE38KDEL distribution will aid in
optimized drug dose deliverance at the tumor site thereby
enhancing the therapeutic eﬃcacy.
3.6. Glycoprotein Nonmetastatic Melanoma Protein B. Glyco-
protein nonmetastatic melanoma protein B (GPNMB) is a
type I transmembrane protein that was identiﬁed by the
serial analysis of gene expression (SAGE) method as a poten-
tial GBM marker gene [123]. While normal brain samples
expressed little or no GPNMB, 70% (35/50) and 66%
(52/79) of GBM patient tumor samples were positive for the
transcript and protein, respectively [124]. Survival analysis
revealed that patients with relatively high GPNMB trans-
cript levels, >3-fold over normal brain, as well as positive
immunohistochemistry, had a signiﬁcantly higher risk of
death, making GPNMB an ideal target for the treatment of
malignant glioma [124]. Human GPNMB protein is com-
posed of 560 amino acids and is made up of three domains, a
longECD(464aminoacids),asingletransmembraneregion,
and a short cytoplasmic domain (53 amino acids) [124]. An
aﬃnity-matured GPNMB-speciﬁc mutant scFv clone, F6V,
was isolated from a human synthetic phage-display library
[125] .T h eF 6 Vs c F vc l o n ew a sf u s e dt oP E 3 8t og e n e r a t e
theimmunotoxinF6V-PE38.TheF6V-PE38exhibitedsignif-
icant cytotoxicity, IC50 = 8pM, against GPNMB-expressing
glioma cells, D293MG, D54MG, D245MG, and D212MG.
Furthermore, F6V-PE38 delayed tumor growth over 17 days
against subcutaneous malignant glioma xenograft D212MG
[125].
3.7. High-Molecular-Weight Melanoma-Associated Antigen.
The high-molecular-weight melanoma-associated antigen
(HMW-MAA) consists of a 250kDa N-linked glycoprotein
and a proteoglycan component of >450kDa [126]. The 250-
kDa core glycoprotein encompasses a 2222 amino acid ECD,
a 25 amino acid hydrophobic transmembrane region, and
a 75 amino acid cytoplasmic tail [126]. The HMW-MAA8 Clinical and Developmental Immunology
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Figure 1:T1-weightedsignalofMR1-1-PE38KDEL(aandc),comparedwithmeasuredconcentrationproﬁleofGd-DTPA(bandd).(a)T1-
weightedsignalofMR1-1-PE38KDELat24hours.(b)ConcentrationofGd-DTPAat24hours.(c)T1-weightedsignalofMR1-1-PE38KDEL
at 72 hours. (d) Concentration of Gd-DTPA at 72 hours. Gd-DTPA, gadolinium-diethylene triamine pentaacetic acid. Reprinted from [122]
with permission from Wolters Kluwer Health (license number 2747070143830).
expressionhasbeendemonstratedonmalignantgliomasand
is recognized by the mAb 9.2.27 [127]. The 9.2.27 mAb was
chemically conjugated to the whole PE molecule to obtain
9.2.27-PE. Intratumoral treatment of established human
glioma xenografts in nude rats with 9.2.27-PE IT extended
the survival of these animals from 30% to 90% [128]. The
HMW-MAA is also recognized by the mAb Mel-14 [129].
In an immunohistochemical analysis, 28 of 49 (57%) GBM
patient specimens exhibited Mel-14 reactivity [130]. The
131I-labeled Mel-14 F(ab )2 fragments were successfully tes-
ted in a Phase I clinical trial for neoplastic meningitis in a
46-year-old female who exhibited no radiographic evidence
of disease, 4 years posttreatment [131, 132]. The Mel-14 scFv
has been fused to PE38-KDEL to generate the immunotoxin
Mel-14-PE38KDEL for targeted therapy of GBM expressing
HMW-MAA [133].
3.8. EphA2. The Eph receptors consisting of 14 members are
thelargestfamilyoftyrosinekinasereceptorsandaredivided
on the basis of sequence similarity and ligand aﬃnity into
A- and B-subclass. The ligands for Eph receptors, termed
ephrins,aredividedintotheephrin-Asubclass(bindsA-type
receptor), which are glycosylphosphatidylinositol-linked
proteins, and the ephrin-B subclass (binds B-type recep-
tor), which are transmembrane proteins [134, 135]. Eph
receptorsandephrinsarebothmembranebound,andhence,
binding and activation of Eph and ephrins requires cell-cell
interactions. Several biological functions, including vascular
development, tissue-border formation, cell migration, axon
guidance, and synaptic plasticity, have been attributed to
Eph/ephrin interaction [135]. EphA2 is overexpressed in
a number of solid tumors, including those of the breast,
prostate, ovary, and pancreas [136]. The EphA2 receptorClinical and Developmental Immunology 9
expression is also elevated in about 90% of GBM specimens
and cell lines, while ephrinA1 is present at consistently low
levels [137]. The EphA2 ligand ephrinA1 was chemically
linked to PE38QQR. The cytotoxin ephrinA1-PE38QQR
exhibited signiﬁcant killing of GBM cells overexpressing
the EphA2 receptor, with an average IC50 of ∼10−11mol/L
[136].
3.9. Urokinase-Type Plasminogen Activator Receptor. The
urokinase-type plasminogen activator receptor (uPAR) is an
important regulator of extracellular matrix (ECM) prote-
olysis, cell-ECM interactions, and cell signaling. uPAR is a
member of the lymphocyte antigen 6 (Ly-6) superfamily of
proteins, which is characterized by the Ly-6 and uPAR (Lu)
domain. uPAR contains three Lu domains, designated D1–
D3, connected by short linker regions [138]. The uPAR is
associated with the external surface of the plasma membrane
by a glycosyl phosphatidylinositol anchor. uPAR regulates
the activity of the plasminogen activation system by binding
to the amino-terminal growth factor domain of the serine
protease urokinase-type plasminogen activator (uPA) [138].
uPARisexpressedinmanyhumancancers,includingbladder
cancer, breast cancer, prostate cancer, colorectal cancer, gas-
tric cancer, lung cancer, pancreatic cancer, glioblastoma,
leukemia, and lymphoma [138]. Expression frequently indi-
cates poor prognosis and in some cases is predictive of inva-
sion and metastasis. A recombinant fusion protein, DTAT,
containing the catalytic portion of DT for cell killing fused to
the amino-terminal (AT) fragment of uPA, was tested for its
eﬀectiveness against uPAR-positive human GBM cells [139].
DTAT exhibited signiﬁcant killing of uPAR-expressing GBM
cells,U118MGandU87MG,invitroandcausedastatistically
signiﬁcant(P = 0.05)regressionofsmallU118MGtumorsin
athymic nude mice, in vivo [139].
3.10. Bispeciﬁc Cytotoxins. To improve the eﬃcacy of antigli-
oblastoma therapeutics, bispeciﬁc cytotoxins targeting two
diﬀerent antigens on tumor cells are being developed. A bis-
peciﬁc cytotoxin, DTEGF13, was constructedby fusing IL-13
to EGF and catalytically active truncated DT (DT390)i na
single polypeptide chain [140]. Intratumoral injection of
DTEGF13, but not monospeciﬁc DTEGF or DTIL13, signif-
icantly inhibited the growth of established U87 tumors in
nude mice (P<0.04) [140].
A second bispeciﬁc cytotoxin, EGFATFKDEL 7mut, was
created by splicing EGF and amino-terminal fragment of
uPAR (ATF) to a version of PE38KDEL in which the seven
major immunodominant epitopes in PE38 were mutated to
decrease toxin immunogenicity without a loss of catalytic
activity [141]. Intracranial treatment of human GBM xeno-
graft, U87, in athymic nude rats with EGFATFKDEL 7mut
via CED led to signiﬁcant reductions in tumor growth in two
independent experiments (P<0.01) [141]. Some rats re-
mained tumor free over 130 days posttumor inoculation.
A bispeciﬁc cytotoxin DTAT13 was also synthesized in
order to target simultaneously uPAR and IL-13R-expressing
GBM cells. DTAT13 caused the regression of small tumors
and was able to target both IL-13R and uPAR with less toxi-
city than DTAT or DTIL13 [142].
4. FutureDirections
The therapeutic success of a tumor-targeting agent is inﬂu-
enced by several factors: selective killing of tumor cells in
the absence of nonspeciﬁc toxicity, successful delivery of the
immunotoxin to tumor cells, and ﬁnally, blocking the gen-
eration of anti-immunotoxin antibodies. Many of the mole-
cular targets for immunotoxins are signiﬁcantly overexpres-
sed on the tumor cells but are also expressed on normal tis-
sues, usually at a much lower level than on the tumor. Hence,
it is essential to minimize the toxic eﬀects of an immuno-
toxin owing to bystander cell death. The CED of macro-
molecules directly into the brain circumvents the blood-
brain barrier, minimizes systemic exposure, with eﬃcient
intratumoral drug delivery and high local and peritumoral
drug concentrations. The next concern is the successful con-
veyance of targeted toxins to tumor cells. Although CED
provides the best volume of distribution of a locally adminis-
tered drug, speciﬁc regions of the brain are naturally diﬃcult
to saturate completely with the infusate. Successful drug
delivery will therefore depend on the proper placement of
catheters. Advances in imaging and computational models
will help to predict therapeutic agent distribution by CED
and consequently can be used to optimize catheter position-
ing [143]. Moreover, imaging of therapeutic agent delivery
during CED is essential to prove drug delivery to the inten-
ded target area [122]( Figure 1). A major disadvantage is that
patients may develop neutralizing antibodies against toxins
which prevent retreatment. To avoid the production of neu-
tralizing antibodies against PE and to allow for more treat-
ment cycles, a less immunogenic form of the PE38 has been
generated by identifying and eliminating the B-cell epitopes
on PE38 [144]. The new PE38 molecule has signiﬁcantly less
immunogenicitybutstillretainsfullcytotoxicandantitumor
activities.
Brain tumors are highly heterogeneous, with multiple
geneticalterations,andhencenotumorantigenisexclusively
present on all tumor cells. Rather, it is a combination of anti-
gens that deﬁnes the cells that make up the tumor popula-
tion. With single-agent therapy, cancers tend to recur owing
to overexpression of a diﬀerent tumor antigen. Hence it is
essential that a therapeutic regimen incorporate a cocktail of
immunotherapeutic agents aimed at diﬀerent cellular targets
critical for brain tumor development, growth, and invasion.
However,combinationtherapiesinvolvingmultipleantibod-
ies involve high development, manufacturing, and treatment
costs. To overcome these diﬃculties, bispeciﬁc antibodies
with diﬀerent antigenic speciﬁcities are under development.
As discussed above, the clinical utility and eﬃcacy of bispe-
ciﬁc antibody-based therapy is still in its infancy, with the
majority of supporting evidence emerging from preclinical
studies. The therapeutic success of a bispeciﬁc antibody in
the clinical setting depends on the identiﬁcation of the ap-
propriate antigenic target combinations and the ability to
produce suﬃcient quality and quantity of the therapeutic
material.
An alternative treatment strategy for brain tumor pa-
tients involves selective targeting of tumor cells by radioim-
munotherapy (RIT). A potential advantage with RIT is the10 Clinical and Developmental Immunology
bystander eﬀect of radiation, that is, depending on the path
lengthofdiﬀerentisotopesitcankilladjacenttumorcellsnot
expressing the target antigen. Several successful phase I and
phase II trials in brain tumor patients with anti-tenascin
mAbs BC-2, BC-4, and 81C6 labeled with the β-emitters,
131Ia n d90Y, and the α-emitter, 211At, demonstrated the the-
rapeuticpotentialofRIT[145].Further,a46-year-oldfemale
with neoplastic meningitis was successfullytreated in a phase
I clinical trial with 131I-labeled Mel-14 F(ab )2 targeting the
HMW-MAA [132]. The therapeutic utility of mAbs target-
ing GAAs, EGFR, EGFRvIII, and podoplanin has been suc-
cessfully demonstrated at the preclinical level [146, 147]. The
RIT trials speciﬁed above involved locoregional adminis-
tration of the radiolabeled mAbs. Optimization of RIT for
future clinical trials involves the identiﬁcation of an ideal
radionucleotide and dosing regimen, along with improved
intracerebral microinfusion by CED.
5. Conclusion
The present generation of targeted toxins has resulted from
years of work by numerous investigators who have engi-
neered these drugs to bind to receptors with reduced in vivo
toxicity and immunogenicity. Immunotoxins exhibit a dif-
ferent mechanism of action than traditional chemotherapy
and radiation therapy, hence might act synergistically with
theseformsoftreatmentwithoutsubsequentcumulativeside
eﬀects. Further progress and improved clinical response
depends on the identiﬁcation of new antigenic targets on
tumors and on administering a combination of immunotox-
ins or bispeciﬁc immunotoxins that target diﬀerent tumor
antigens.
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